Atreca, Inc(PINK:BCEL) 
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery...
Website: http://www.atreca.com
Founded: 2010
IPO Price: $17 (Jun 20, 2019)
Full Time Employees: 128
CEO: John A. Orwin
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2023-12-20
P
O 0.24
H 0.25
L 0.23
C 0.24
V 259,711
10EMA 0.24
20EMA 0.24
60EMA 0.24
120EMA 0.24
250EMA 0.24